3.57BMarket Cap-6.05P/E (TTM)
38.440High37.670Low781.97KVolume37.970Open37.980Pre Close29.77MTurnover0.86%Turnover RatioLossP/E (Static)93.90MShares60.37052wk High14.00P/B3.45BFloat Cap29.59052wk Low--Dividend TTM90.53MShs Float179.647Historical High--Div YieldTTM2.03%Amplitude29.590Historical Low38.068Avg Price1Lot Size
Ultragenyx Pharmaceutical Stock Forum
Breakthrough: Ultragenyx's Gene Therapy Reverses Cognitive Decline in Fatal Childhood Disease
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that the European Commission has extended the approval of Evkeeza® (evinacumab) to treat children aged 6-months and older with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first medicine in the EU approved f...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$